Results of radical prostatectomy performed in patients with and above age specific ranges of PSA (AS PSA)
Article published in Urologia Polska 2005/58/4.
Mieczysław Fryczkowski, Zofia Krauze-Balwińska, Andrzej Paradysz, Tomasz Pawlikowski, Maciej Szczębara
- Katedra i Klinika Urologii w Zabrzu ¦l±skiej Akademii Medycznej w Katowicach
Kierownik kliniki: prof. dr hab. Mieczysław Fryczkowski
prostate, prostate cancer, AS PSA, radical prostatectomy
- The risk of prostate cancer progression in patients after radical prostatectomy (RP), who had TPSA within the limits of AS PSA before the operation, is similar to the patients with TPSA Ł4 ng/ml. It is lower than in patients with higher TPSA. The aim of this paper was to provide comparative evaluation of the results in these two separate groups.
- materials and methods
- 25 (19.1%) patients with AS PSA (first group) have been subjected to analysis as well as 106 (80.9%) patients with higher values of T PSA (second group). The analysis encompassed clinical factors (age, recurrencer, metastases, deaths) and morphological ones (Gleason Grading Scale - GS, the rate of histopathological changes in prostate together with surgical margin). Follow-up ranged from 7 to 108 months (42.1 months on average).
- It has been stated that patients with AS PSA had substantially lower rate of advanced forms of prostate cancer. However, no differences in clinical and morphological progression after the operation have been reported as compared to the patients of the second group. A strong independent factor affecting progression in both groups was GS with a border value 7.
- 1. Prostate cancer in the first group of patients is characterized by statistically significant lower rate of clinically advanced forms.
- 2. No statistically significant differences have been reported within the field of progression between patients both groups.
- 3. GS value with its border value of 7 which is significant factor which increased the rate of advanced forms of PC and the risk of progression in both analyzed patients groups.
- 4. Summary value of Gleason scale with border value > 7 is a significant factor which influenced the rate of clinically advanced forms, and progression of PC. It also reduced 5-year survival time in both analyzed groups of patients.
- Oesterling JE, Jacobsen SJ, Chutel Get et al: Serum PSA in a community based population of healthy men. Establishment of age specific reference ranges. JAMA 1993, 270, 860-864.
- Gold MH, Brauer MK: The PSA the most effective serum tumor marker in oncology in: Belldegruna A, Kirby R, Oliver Z (ed). New Perspectives in prostate cancer. Oxford, ISIS Medical Media 1996, 117-128.
- Etzioni R, Shen Y, Patteway JC et al: Age-specific prostate-specific antigen: a reassessment. Prostate Suppl. 1996, 7, 70-77.
- Huidobro C, Acevedo C, Cobezas J: Prostate cancer diagnosis in patients with PSA level between 2,5-4,0 ng/ml. Eur Urol 2001, 39, suppl. 2, abstr. 646.
- Funo M, Sokoloff MR, Ahoon D et al: Prostate cancer (PC) in men with normal prostate specific antigen (PSA) level. J Urol 2001, 165, suppl. 5, abstr. 1362.
- D?Amico AV, Chen MK, Malkowicz SD et al: Lower prostate antigen specific outcome the expectant following radical prostatectomy in patients with high grade prostate cancer and prostate antigen level of 4 ng/ml or less. J Urol 2002, 167, 2025-2030.
- Reissigl A, Pointner J, Horninger W et al: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology 1995, 46, 662-665.
- Rochl KA, Antenor JA, Catalona WJ et al: Preoperative PSA level is significantly associated with the interval to biochemical progression following radical prostatectomy. J Urol 2004, 169, suppl. 4, abstr. 1074.
- Berger A, Spranger R, Stainer H et al: Early detection with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Eur Urol 2003, 39, suppl. 2, abstr. 503.
- Epstein J, Walsh PC, Carmichael M, Brendler CH: Pathologic and clinical findings to predict tumor extent of nonpalpable /stageT1c/ prostate cancer. JAMA 1994, 27/5, 368-374.
- Severi G, Horninger W, Berger A et al: Age related reference ranges for total serum PSA in an asymptomatic early prostate cancer detected population. Eur Urol 2003, 39, suppl. 2, abstr. 728.
- Goł±b A, Słojewski M, Gliniewicz B i in: Porównanie stopnia zło¶liwo¶ci raka prostaty według Gleasona w materiale biopsyjnym i operacyjnym po radykalnej prostatektomii. Urol Pol 2003, 56, 2A, abstr. Ap-3.
- Noldus J, Stamey TA: Histological characteristic of radical prostatectomy in men with serum prostate specific antigen of 4 ng/ml or less. J Urol 1996, 155, 441-443.
- O?Dowd GJ, Miller MC, Veltri RW et al: Comparison of diagnostic performance of complexed PSA vs f/TPSA ratio in a contemporary referal population with a total PSA range of 2.0-8.0 ng/ml. J Urol 2001, 165, suppl. 5, abstr. 1307.
- Djavan B, Zlotta A, Kratzik C et al: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999, 54, 517-522.
- Raaijmakers H, Blijenberg BJ, Finley JA et al: Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004, 171, 2245-2249.
- Keetch DW, Arcangeli CG, Catalona WJ et al: Morphometric analysis of prostate cancer from men with a normal DRE and PSA value of 2.5-4.0 ng/ml. J Urol 1997, 157, suppl. 4, abstr. 902.
- Horninger W, Rogatsch H, Volgger H et al: Staging and histopathology of prostate cancer with total PSA levels below 3,99 ng/ml. J Urol 2001, 165 suppl. 5, abstr. 997.
- Horninger W, Volgger H, Rogatsch H et al: Comparison of TLC prostate cancer patients with PSA levels below and above 4 ng/ml and Gleason scores equal or below 6. J Urol 2001, 165, suppl. 5, abstr. 988.
- Theiss M, Langer PW, Hofmackel G et al: Histological findings and prognosis in patients with prostate antigen (PSA) below 4 ng/ml undergoing radical prostatectomy. Eur Urol 1996, 30, suppl. 4, abstr. 612.
Klinika Urologii ¦AM
ul. 3 Maja 13/15
tel./fax 032 271 65 11